Towards understanding mare endometrosis: ex vivo study on the role of relaxin
Reproduction, Fertility and Development · 2025
DOI: 10.1071/rd25166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproduction, Fertility and Development, 2025. Verfasst von Magdalena Profaska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostics and Clinical Sciences, Faculty of Veterinary Medicine, University of Agriculture in Krakow, Krakow, Poland. Hauptthemen laut MEDLINE: Relaxin, Endometrium, Endometriosis, Horse Diseases. Die Arbeit nennt 86 Literaturangaben.
Abstract (Originalsprache)
Context
Mare endometrosis remains a poorly understood pathological process.
Aims
Mare endometrial tissue with endometrosis was used to determine the effects of relaxin (RLX). Healthy tissues that were left untreated (H), or treated with vehicle (Hveh), and tissues with endometrosis that were left untreated (E), treated with vehicle (Eveh), and treated with RLX (10, 25, 50 nM; ER) were used for an ex vivo system for 72 h.
Methods
Tissue histological examination, and immunoenzymatic measurement of the concentrations of transforming growth factor β (TGF-β), interleukins (IL-6 and IL-8), and progesterone were performed. Western blotting was used to study the abundance of the following proteins involved in cellular processes, signaling, and interactions: N-cadherin, cortactin, Wnt/β-catenin signaling with kinases: glycogen synthase kinase-3β (GSK-3β), protein kinase B (AKT), metalloproteinases: MMP9, MMP2, and cyclins: D1, D3. Key results RLX (50 nM) decreased the concentration of TGF-β, increased concentrations of IL-6 and IL-8, and decreased the concentration of progesterone, without histological alterations of the treated tissues. Interactions of RLX with proteins showed changes in protein abundance, as follows: N-cadherin increased, cortactin increased, β-catenin, GSK-3β and AKT showed an increase of phosphorylation, MMP2 and MMP9 increased, and cyclin D3 increased in ER versus E.
Conclusions
Results indicated that RLX exerted both anti-/pro-inflammatory as well as anti-/pro-fibrotic effects depending on interacting cytokine/protein.
Implications
In equine breeding, the application of RLX with marker protein antagonists/agonists may be promising in endometrial fibrosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostics and Clinical Sciences, Faculty of Veterinary Medicine, University of Agriculture in Krakow, Krakow, Poland.
- Chair of Medical Biochemistry Jagiellonian University Medical College, Krakow, Poland.
- Department of Infectious Diseases of Animals and Food Hygiene, Faculty of Veterinary Medicine University of Agriculture in Krakow, Krakow, Poland.
- Department of Veterinary Anatomy and Physiology, University of Nairobi, Nairobi, Kenya.
- Deparment of Animal Surgery and Theriogenology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Hanoi, Vietnam.
- Department of Basic Sciences, Faculty of Veterinary Medicine, University of Agriculture in Krakow, Krakow, Poland.
ORCID-Profile: Malgorzata Kotula-Balak
Zitieren
APA
Profaska, M., Zarzycka, M., Dubniewicz, K., Witkowski, M., Wieczorek, J., Gil, D., Wafula, S., Lanh, D. K., & Kotula-Balak, M. (2025). Towards understanding mare endometrosis: ex vivo study on the role of relaxin. Reproduction, Fertility and Development. https://doi.org/10.1071/rd25166
Vancouver
Profaska M, Zarzycka M, Dubniewicz K, Witkowski M, Wieczorek J, Gil D, et al. Towards understanding mare endometrosis: ex vivo study on the role of relaxin. Reproduction, Fertility and Development. 2025. doi:10.1071/rd25166
BibTeX
@article{Profaska2025,
author = {Profaska, Magdalena and Zarzycka, Marta and Dubniewicz, Klaudia and Witkowski, Maciej and Wieczorek, Jaroslaw and Gil, Dorota and Wafula, Samwel and Lanh, Do Kim and Kotula-Balak, Malgorzata},
title = {Towards understanding mare endometrosis: ex vivo study on the role of relaxin},
journal = {Reproduction, Fertility and Development},
year = {2025},
doi = {10.1071/rd25166}
}
EUVIMED